In just under six weeks, one of the generics and biosimilars industry’s leading players will be under new management, after Teva announced that former Sandoz chief Richard Francis would take over from Kåre Schultz as president and CEO of the Israeli firm from 1 January 2023.
The news comes soon after Schultz made it clear that he would not be continuing in the role after his current contract expired, originally set to run to November 2023
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?